Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
clinical trials
life sciences
national blog main
amgen
eli lilly
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
teva pharmaceutical
boston blog main
calcitonin gene-related peptide
chronic migraine
migraine
migraine research foundation
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
episodic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
impel neuropharma
indiana
lasmiditan
medical device
national
national top stories
san diego blog main
san diego top stories
What
drug
5
×
migraine
5
×
approval
fda
new
won
class
companies
decades
developed
eli
lilly
medicines
pain
starts
activity
acute
addresses
amgen
announced
approved
arguments
big
biotech
candidates
causes
commercialized
competitors
condition
days
decision
dog
drugs
firm
friday
gets
giant
giving
hasn’t
head
Language
unset
Current search:
migraine
×
biotech
×
drug
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines